Morphometric and Biochemical Clusters of Metabolic Syndrome in Type 2 Diabetic Patients at Different Stages of Diabetic Retinopathy

V.N. Serdyuk, V.A. Іshchenko

Abstract


Background. We studied the morphometric and biochemical clusters of metabolic syndrome in patients with type 2 diabetes mellitus (DM) at different stages of diabetic retinopathy (DR). Materials and methods. The study included 83 patients (166 eyes) divided into two groups. Results. The morphometric and biochemical clusters study of 59 patients with type 2 DM (mean age 58.2 ± 0.99 years old, the average duration of diabetes 9.19 ± 0.16 years) using dispersion analysis and binomial law demonstrated that DR developed in 83.4 % obsessive patients (with enhanced waist measurement), in 71.4 % hypertensive patients, in 61.9 % patients with hypercholesterinemia, 47.6 % patients with dyslipidemia and 52.3 % patients with hypertriglyceridemia. Further progression of DR is closely associated with hypertension, dyslipidemia against android obesity, hypercholesterolemia and hypertriglyceridemia. Conclusions. The patients with type 2 DM with the proliferative stage of DR are at increased risk of occurrence of cardiovascular events, including the ocular fundus. This should be considered in surgical, physiotherapy and medication treatment.


Keywords


diabetic retinopathy; metabolic syndrome

References


Arterial hypertension. Renewed and the adapted clinical guidelines based on proofs. Appendix to Order of Health Ministry of Ukraine № 384, 24.05.2012 About a statement and introduction of medical and technological documents from standardization of medicare at arterial hypertension. www.moz.gov.ua/ua/portal/dn_20120524_384.html. (Ukrainian)

DOI: http://dx.doi.org/10.14341/2072-0351-6187 Bodanova AA, Mkrtumyan AM, Davydov AL. et al. Structure of late vascular complications at newly diagnosed of type 2 diabetes mellitus. Diabetes Mellitus. 2006;9(4):35-37. DOI: http://dx.doi.org/10.14341/2072-0351-6187 (Russian)

Guseinova RR, Mirzazade VA. Effect of duration of diabetes mellitus on the prevalence of diabetic retinopathy in patients with type 2 diabetes and metabolic syndrome. Diabetes Mellitus. 2010;13(2):94-96). DOI: http://dx.doi.org/10.14341/2072-0351-5682 (Russian)

Kirilyuk M. Medication of diabetic retinopathy in type 1 diabetes mellitus. Review of the literature and clinical trials. International Journal of Endocrinology. 2012;5(45):70-75 (Russian)

Kyryliuk M, Kostev F, Pidayev A, Shataliuk S. Biometric and biochemical parameters of metabolic syndrome and risk of its occurrence in patients with benign prostatic hyperplasia. Clinical Endocrinology and Endocrine Surgery. 2012;3(40):53-58 (Russian)

Sirenko YM. Target level of blood pressure in patients with type 2 diabetes mellitus. International Journal of Endocrinology. 2012;6(46):10-14 (Ukrainian)

Shestakova MV. The role of the tissue renin-angiotensin-aldosterone system in the development of metabolic syndrome, diabetes mellitus and its vascular complications. Diabetes Mellitus.2010;13(3):14-19. DOI: http://dx.doi.org/10.14341/2072-0351-5481 (Russian)

Catapano AL, Graham I, de Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37(39):2999-3058. doi:10.1093/eurheartj/ehw272.

Chase HP, Garg SK, Jackson WE. et al. Blood pressure and retinopathy in type 1 diabetes. Ophtalmology. 1990;97:155-159.

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J. 2012;33(13):1635-1701.

Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.

Glantz SA. Primer of biostatistics. 4th Edition. McGraw-Hill, New York, St. Louis, San-Francisco, Madrid, Milan, Sydney, Tokyo, Toronto; 1994.

Grundy SM, Cleeman JI, Daniels SR. et al. Diagnosis and Management of the Metabolic Syndrome. Circulation. 2005;112:2735-2752 http://dx.doi.org/10.1161/CIRCULATIONAHA.105.169404.

Klein R, Klein BEK, Moss SE. et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophtalmology. 1998;105:1801-1805.

Kohner EM, Porta M. Screening for diabetic retinopathy in Europe: A field handbook. Boehringer Mannheim, Italy. 1992.

Testa MA, Puklin JE, Sherwin RS. et al. Clinical predictors of retinopathy and its progression in patients with type 1 diabetes during CSII and conventional insulin treatment. Diabetes. 1985;34(3):61-68.

Lakka HM, Laaksonen DE, Lakka TA. et al. The metabolic syndrome and cardiovascular disease mortality in middle–aged men. JAMA. 2002;283:2909-2916.




DOI: https://doi.org/10.22141/2224-0721.7.79.2016.86421

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru